Physician profile
Priya Kumar
NPI 1578501847
$47,767.81
in general payments reported to CMS, 2019-2025
7 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,065 · 2020: $19.42 · 2021: $1,665 · 2022: $3,990 · 2023: $4,891 · 2024: $19K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,746 · Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,567.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,745.70 |
| Food and Beverage | $714.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $23,320.07 | 2022-2025 | Datroway |
| Astrazeneca Pharmaceuticals Lp | $16,833.86 | 2019-2025 | Imfinzi, Lynparza |
| Avyxa Pharma, LLC | $4,171.41 | 2025 | |
| Genzyme Corporation | $1,775.05 | 2022 | |
| Incyte Corporation | $860.00 | 2025 | Jakafi |
| Blueprint Medicines Corporation | $788.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.